Difference between revisions of "Cytarabine and daunorubicin liposomal (Vyxeos)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== This drug is a liposomal formulation of Cytarabine (Cytosar) and Daunorubicin (Cerubidine) in a 5:1 molar ratio. ==Preliminary data== <!-- Pre...") |
m |
||
| Line 5: | Line 5: | ||
<!-- Presented in part in abstract form at the 52nd annual meeting of the American Society of Hematology, Orlando, FL December 4-7, 2010. --> | <!-- Presented in part in abstract form at the 52nd annual meeting of the American Society of Hematology, Orlando, FL December 4-7, 2010. --> | ||
# Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC, Feldman EJ. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014 May 22;123(21):3239-46. Epub 2014 Mar 31. [http://bloodjournal.hematologylibrary.org/content/123/21/3239.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/24687088 PubMed] | # Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC, Feldman EJ. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014 May 22;123(21):3239-46. Epub 2014 Mar 31. [http://bloodjournal.hematologylibrary.org/content/123/21/3239.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/24687088 PubMed] | ||
| + | |||
| + | [[Category:Chemotherapy]] | ||
| + | [[Category:Investigational]] | ||
| + | [[Category:Anthracyclines]] | ||
| + | [[Category:Pyrimidine analogues]] | ||
Revision as of 15:26, 10 June 2014
Mechanism of action
This drug is a liposomal formulation of Cytarabine (Cytosar) and Daunorubicin (Cerubidine) in a 5:1 molar ratio.
Preliminary data
- Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC, Feldman EJ. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014 May 22;123(21):3239-46. Epub 2014 Mar 31. link to original article PubMed